Vertex Pharmaceuticals
VRTX
491 hedge funds and large institutions have $21B invested in Vertex Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 45 funds opening new positions, 190 increasing their positions, 177 reducing their positions, and 34 closing their positions.
32% more first-time investments, than exits
New positions opened: 45 | Existing positions closed: 34
2% more funds holding
Funds holding: 483 → 491 (+8)
9% more call options, than puts
Call options by funds: $95.6M | Put options by funds: $87.9M
7% more repeat investments, than reductions
Existing positions increased: 190 | Existing positions reduced: 177
2% more capital invested
Capital invested by funds: $20.7B → $21B (+$356M)
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
+$208M |
| 2 |
State Street
Boston,
Massachusetts
|
+$155M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$67.2M |
| 4 |
Capital World Investors
Los Angeles,
California
|
+$56.7M |
| 5 |
Morgan Stanley
New York
|
+$50M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GE
General Electric
Evendale,
Ohio
|
-$111M |
| 2 |
JP Morgan Chase
New York
|
-$108M |
| 3 |
American Century Companies
Kansas City,
Missouri
|
-$55.3M |
| 4 |
O
OrbiMed
New York
|
-$54.6M |
| 5 |
D.E. Shaw & Co
New York
|
-$49.9M |
VRTX Hedge Fund Activity: Q3 2016 in Review
491 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Vertex Pharmaceuticals (VRTX) for Q3 2016, worth a combined $21B — up 1.7% from $20.7B a quarter earlier.
Buyers outnumbered sellers: 45 funds opened new VRTX positions and 34 closed out — a net gain of 11 holders — while 190 added to existing stakes and 177 trimmed.
The largest buyer was Jennison Associates, adding an estimated $208M. The largest seller was General Electric, exiting entirely with an estimated $111M sold.
- 491 institutional investors held Vertex Pharmaceuticals (VRTX) as of Q3 2016, up from 483 in Q2 2016.
- Funds reported $21B of Vertex Pharmaceuticals stock for Q3 2016, up 1.7% quarter-over-quarter.
- 45 funds opened new Vertex Pharmaceuticals positions in Q3 2016 and 34 closed out, a net change of +11 holders.
- The largest Vertex Pharmaceuticals buyer in Q3 2016 was Jennison Associates, an estimated $208M added.
- The largest Vertex Pharmaceuticals seller in Q3 2016 was General Electric, an estimated $111M sold.
Based on aggregated 13F filings for Q3 2016.